March 10, 2020 FDA Approves New Treatment for Chronic Fibrosing ILD The U.S. Food and Drug Administration has approved the first-ever treatment for chronic fibrosing interstitial lung disease (ILD), a condition that can affect rheumatoid arthritis patients. The treatment is designed for patients with a form of the disease that progressively worsens over time.   Lung Disease Frequently Fatal in Rheumatoid Arthritis Interstitial lung abnormalities can be detected in half of patients with rheumatoid arthritis. The condition can be chronic and worsen over time, leading to higher rates of mortality in RA patients with the disease.   Coronavirus as Risk Factor for Rheumatoid Arthritis Respiratory viral infections can be a novel environmental risk factor for the development of rheumatoid arthritis, find Korean researchers writing in Arthritis Research and Therapy.   RHEUMATOLOGY HEALTHCARE JOB OPPORTUNITIES Visit Rheumatology Network for easy access to new job opportunities in rheumatology. As a service to our readers, we've posted a national "Job Board" in the upper right-hand corner of the site. Suggestions for other content sections? Email the editor at areyes@mmhgroup.com.